Form 4: BioMarin Legal Officer Reports Equity Transactions

BioMarin Pharmaceutical's EVP, Chief Legal Officer, George Eric Davis, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax purposes.

Summary

• George Eric Davis, EVP, Chief Legal Officer of BioMarin Pharmaceutical Inc. (BMRN), reported transactions on March 16, 2026.
• Davis disposed of 7,177 shares of Common Stock at a price of $58.51 per share, likely for tax withholding related to equity vesting.
• Davis acquired 14,570 shares of Common Stock through a Restricted Stock Unit (RSU) grant, with a transaction price of $0.
• Davis also acquired 34,690 Stock Options (Right to Buy Common Stock) with an exercise price of $57.43 per share, with a transaction price of $0.
• Following these transactions, Davis directly beneficially owns 79,833 shares of Common Stock and 34,690 Stock Options.
• A clerical error from a previous report was corrected, adjusting direct holdings by thirteen shares.
• The option grant vests 12/48th on March 16, 2027, and 1/48th on the 16th day of each month thereafter, expiring on March 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine executive compensation transactions (grants of RSUs and options) and a standard disposition of shares for tax withholding, which are common and expected events for public company executives.

Positives

• The grant of 14,570 Restricted Stock Units and 34,690 Stock Options aligns the executive's interests with long-term shareholder value.
• The acquisition of equity compensation demonstrates continued commitment and incentivization for the Chief Legal Officer.

Negatives

• The disposition of 7,177 shares of Common Stock at $58.51 was for tax withholding purposes, which is a routine event and not indicative of a negative outlook.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, aligning their financial interests with the company's long-term performance and shareholder returns.

Stakeholder Impact

• Shareholders: The equity grants align the executive's interests with shareholder value creation over the long term.
• Employees: This filing primarily concerns executive compensation and does not directly impact the broader employee base beyond general compensation practices.

Next Steps

• The stock options will vest according to a schedule: 12/48th on March 16, 2027, and 1/48th on the 16th day of each month thereafter.

Key Dates

Keywords

BMRN, BioMarin Pharmaceutical, Insider Transaction, Form 4, Executive Compensation, Restricted Stock Units, Stock Options, Equity Grant